gSpiriva Delivers First Mover Advantage In US, Lupin Plans Europe Launch
Lucentis Biosimilar Filing Seen In FY25
Executive Summary
Lupin’s Q2 margins jumped post launch of the first Spiriva generic in the US, encouraging launch plans for Europe and Canada. With four out of five plants clearing a regulatory overhang from earlier warning letters, the specialty engine is revving up though competition in first-to-file products launched earlier could dampen margins somewhat
You may also be interested in...
A Decade At The Top: Lupin MD On Listing Adjacencies, Creating Healthcare Continuum
As family-led firms go through a churn in India, Lupin’s MD Nilesh Gupta speaks about adding value via adjacencies to the legacy business, building digital interfaces and a healthcare continuum for patients. In an interview with Scrip, he also emphasized Lupin promoters are neither interested in selling their own stake nor in acquiring that of Cipla’s promoters.
Lupin Seeks Anti-Obesity Drug Alliances While Aiming For No.2 Spot In Diabetes
In an interview with Scrip, Lupin’s MD Nilesh Gupta spoke about seeking alliances to address the anti-obesity market in India post a demand surge for Wegovy and Mounjaro, the company’s thrust into pharma-adjacent businesses, the limited impact so far of the Israel-Palestine conflict on Indian pharma and more.
Lupin Looks To Next Generation In Narcolepsy With Tentative US Xywav Nod
Lupin may enjoy 180 days of market exclusivity for its proposed generic to Jazz’s next-generation Xywav treatment for sleep disorders.